KalGene has developed an anti-amyloid therapy to slow the progression of Alzheimer’s disease that overcomes the safety issues inherent with antibody-based approaches, including Biogen’s Aducanumab, is more effective and requires less product for efficacy.

KG207 is a bi-specific fusion protein that targets the neurotoxic amyloid- β42 oligomeric peptides that are thought to be neurotoxic and are precursors to abundant amyloid plaques seen in the brains of Alzheimer’s patients.